Effects of Oxcarbazepine and Levetiracetam on Calcium, Ionized Calcium, and 25-OH Vitamin-D3 Levels in Patients with Epilepsy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: The primary objective of the present study was to further elucidate the effects of oxcarbazepine (OXC) and levetiracetam (LEV) monotherapies on the bone health status of patients with epilepsy. Methods: This study included 48 patients who attended our epilepsy outpatient clinic, had a diagnosis of epilepsy, and were undergoing either OXC or LEV monotherapy and 42 healthy control subjects. The demographic and clinical features of the patients, including gender, age, onset of disease, daily drug dosage, and duration of disease, were noted. Additionally, the calcium, ionized calcium, and 25-OH vitamin-D3 levels of the participants were prospectively evaluated. Results: The 25-OH vitamin-D3, calcium, and ionized calcium levels of the patients taking OXC were significantly lower than those of the control group. These levels did not significantly differ between the patients taking LEV and the control group, but there was a significant negative relationship between daily drug dose and ionized calcium levels in the LEV patients. Conclusion: In the present study, anti-epileptic drugs altered the calcium, ionized calcium, and 25-OH vitamin-D3 levels of epilepsy patients and resulted in bone loss, abnormal mineralization, and fractures. These findings suggest that the calcium, ionized calcium, and 25-OH vitamin-D3 levels of patients with epilepsy should be regularly assessed.
Abstract
Objective: The primary objective of the present study was to further elucidate the effects of oxcarbazepine (OXC) and levetiracetam (LEV) monotherapies on the bone health status of patients with epilepsy. Methods: This study included 48 patients who attended our epilepsy outpatient clinic, had a diagnosis of epilepsy, and were undergoing either OXC or LEV monotherapy and 42 healthy control subjects. The demographic and clinical features of the patients, including gender, age, onset of disease, daily drug dosage, and duration of disease, were noted. Additionally, the calcium, ionized calcium, and 25-OH vitamin-D3 levels of the participants were prospectively evaluated. Results: The 25-OH vitamin-D3, calcium, and ionized calcium levels of the patients taking OXC were significantly lower than those of the control group. These levels did not significantly differ between the patients taking LEV and the control group, but there was a significant negative relationship between daily drug dose and ionized calcium levels in the LEV patients. Conclusion: In the present study, anti-epileptic drugs altered the calcium, ionized calcium, and 25-OH vitamin-D3 levels of epilepsy patients and resulted in bone loss, abnormal mineralization, and fractures. These findings suggest that the calcium, ionized calcium, and 25-OH vitamin-D3 levels of patients with epilepsy should be regularly assessed.
참고문헌 (25)
- Hauser WA, "Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota", Mayo Clin Proc, 71, pp.576~586 (1996)
- Adams RD, "Principles of neurology", pp.331~365 (2001), McGraw-Hill
- Dawodu A, "Pilot study of sunlight exposure and vitamin D status in Arab women of childbearing age", East Mediterr Health J, 17, pp.570~574 (2011)
- Verrotti A, "Bone and calcium metabolism and antiepileptic drugs", Clin Neurol Neurosurg, 112, pp.1~10 (2010)
- Deckers CL, "Current limitations of antiepileptic drug therapy: a conference review", Epilepsy Res, 53, pp.1~17 (2003)
- Elliott JO, "Bone loss in epilepsy: barriers to prevention, diagnosis, and treatment", Epilepsy Behav, 8, pp.169~175 (2006)
- Souverein PC, "Incidence of fractures among epilepsy patients:a population-based retrospective cohort study in the General Practice Research Database", Epilepsia, 46, pp.304~310 (2005)
- Pack AM, "Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications", CNS Drugs, 15, pp.633~642 (2001)
- Pack AM, "Epilepsy and bone health in adults", Epilepsy Behav, 5(Suppl 2), pp.S24~S29 (2004)
- Souverein PC, "Use of antiepileptic drugs and risk of fractures:case-control study among patients with epilepsy", Neurology, 66, pp.1318~1324 (2006)
- Verrotti A, "Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine", Epilepsia, 43, pp.1488~1492 (2002)
- Svalheim S, "Bone health in adults with epilepsy", Acta Neurol Scand Suppl, (191), pp.89~95 (2011)
- Miziak B, "The problem of osteoporosis in epileptic patients taking antiepileptic drugs", Expert Opin Drug Saf, 13, pp.935~946 (2014)
- O. Babacan, "May Long Term Oxcarbazepine Treatment Be Lead to Secondary Hyperparathyroidism?", Journal of Clinical Neurology, 8(1), pp.65~68 (2012), 대한신경과학회
- Cansu A, "Evaluation of bone turnover in epileptic children using oxcarbazepine", Pediatr Neurol, 39, pp.266~271 (2008)
- Bauer S, "Early detection of bone metabolism changes under different antiepileptic drugs (EDBoM-AED)--a prospective multicenter study", Epilepsy Res, 106, pp.417~422 (2013)
- Koo DL, "Effect of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy", Epilepsy Res, 108, pp.442~447 (2014)
- Mintzer S, "Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine", Epilepsia, 47, pp.510~515 (2006)
- Cetinkaya Y, "The effect of oxcarbazepine on bone metabolism", Acta Neurol Scand, 120, pp.170~175 (2009)
- Koo DL, "Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy", Epilepsy Res, 104, pp.134~139 (2013)
- Lee R, "The association of newer anticonvulsant medications and bone mineral density", Endocr Pract, 14, pp.1~22 (2012)
- Nissen-Meyer LS, "Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism", Epilepsia, 48, pp.1850~1860 (2007)
- Nissen-Meyer LS, "How can antiepileptic drugs affect bone mass, structure and metabolism? Lessons from animal studies", Seizure, 17, pp.187~191 (2008)
- Beniczky SA, "Bone mineral density in adult patients treated with various antiepileptic drugs", Seizure, 21, pp.471~472 (2012)
- Drezner MK, "Treatment of anticonvulsant drug-induced bone disease", Epilepsy Behav, 5(Suppl 2), pp.S41~S47 (2004)